The Pharmacy Times® Respiratory Syncytial Virus Resource Center is a comprehensive source for clinical news and expert insights on treating and preventing respiratory syncytial virus.
December 23rd 2024
Pharmacists are essential in preventing the significant health and economic burden of respiratory syncytial virus (RSV) infections in older adults through vaccination.
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Pneumococcal Disease Prevention for Older Adults and the Pharmacist’s Role in an Evolving Vaccine Landscape
1.0 Credit / Immunization, Infectious Diseases
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
The Role of the Pharmacist in Influenza Prevention for At-Risk Adults: Strategies to Enhance Immunization
1.5 Credits / Infectious Diseases
View More
The Essential Role of Pharmacists in Improving Influenza Vaccination Coverage: Strategies to Increase Vaccine ...
1.0 Credit / Immunization, Infectious Diseases
View More
The Role of Pharmacists in Pneumococcal Prevention: Strategies to Improve Vaccine Uptake
1.0 Credit / Immunization, Infectious Diseases, Pulmonology
View More
Insights in Influenza Immunization: The Long-Term Care Pharmacist’s Role in Improving Health Outcomes in At-Ri...
1.0 Credit / Immunization, Infectious Diseases
View More
RSV Vaccine Efficacy in Pregnancy
July 2nd 2024Carrie Koenigsfeld, PharmD, FAPhA, highlights the main findings from the MATISSE trial, which evaluated the safety and efficacy of a non-adjuvanted RSV vaccine administered to pregnant women, presenting data that suggests the vaccine's effectiveness in preventing severe RSV in infants and discussing the observed adverse events in both mothers and infants.
Watch
Non-adjuvant RSV Vaccine in Older Adults
June 25th 2024An RSV medical expert provides an overview of the RENOIR trial, which investigated the efficacy and safety of an adjuvanted RSV vaccine in adults aged 60 years and older, focusing on the vaccine's effectiveness in preventing RSV-associated lower respiratory tract infections and presenting other crucial findings from the study.
Watch
Adjuvant RSV Vaccine in Older Adults
June 25th 2024Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.
Watch
CDC Evaluates Concerns of Guillain-Barré Syndrome Following RSV Vaccination
June 17th 2024Data show that among individuals 60 years and older, the estimated rate of Guillain-Barré syndrome (GBS) after receiving an RSV vaccine was 5.0 and 1.5 per million doses of Abrysvo and Arexvy, respectively.
Read More